结构化方法解决PI-RADS v2.1评分与靶向前列腺活检结果不一致:质量改进的契机
回顾性分析392例3T多参数MRI后融合活检患者,评估PI-RADS v2/2.1与靶向活检一致性,PI-RADS 5对临床显著前列腺癌的阳性预测值为0.63;影像复审可解释部分不一致,作者提出多学科复审的结构化质量改进路径。
要点
- PI-RADS 5病灶对临床显著前列腺癌的阳性预测值为0.63,并非100%。
- PI-RADS 5、4、3对临床显著前列腺癌的阳性预测值分别为0.63、0.33、0.09。
- 影像复审可将部分不一致归为评分降级所致,校正后PI-RADS 5阳性预测值升至0.83。
核心结论
- PI-RADS 5病灶对临床显著前列腺癌的阳性预测值并非100%,靶向活检结果不一致时构成诊断困境;影像复审可解释部分不一致,作者提出采用多学科复审影像与存档活检针道的结构化质量改进路径。
研究设计与样本
- 回顾性研究,纳入392例在3特斯拉行多参数MRI后接受融合活检的患者,由对前列腺多参数MRI有专长的放射科医生对不一致病例进行复审。
诊断标准与关键数值
- PI-RADS 5、4、3病灶对所有前列腺癌的阳性预测值分别为0.80、0.55、0.24,对临床显著前列腺癌的阳性预测值分别为0.63、0.33、0.09;校正复审降级的不一致后,PI-RADS 5对临床显著前列腺癌的阳性预测值为0.74,再校正未解决不一致病例中发现的临床显著前列腺癌后升至0.83。
临床应用与阅片要点
- 作者提出采用多学科复审影像与存档活检针道的结构化路径作为解决活检结果不一致的质量改进途径。
局限性
- 原文未报告局限性;作者指出需进一步研究以确定未解决不一致病例中再次活检的价值,并开发稳健的前列腺MRI质量改进系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Prostate multiparametric magnetic resonance imaging (mpMRI) can identify lesions within the prostate with characteristics identified in Prostate Imaging Reporting and Data System (PI-RADS) v2.1 associated with clinically significant prostate cancer (csPCa) or Gleason grade group (GGG) ≥ 2 at biopsy.
OBJECTIVE: To assess concordance (PI-RADS 5 lesions with csPCa) of PI-RADS v2/2.1 with targeted, fusion biopsy results and to examine causes of discordance (PI-RADS 5 lesions without csPCa) with aim to provide a structured approach to resolving discordances and develop quality improvement (QI) protocols.
METHODS: A retrospective study of 392 patients who underwent mpMRI at 3 Tesla followed by fusion biopsy. PI-RADS v2/2.1 scores were assigned to lesions identified on mpMRI and compared to biopsy results expressed as GGG. Positive predictive value (PPV) of PI-RADS v2/2.1 was calculated for all prostate cancer and csPCa. Discordant cases were re-reviewed by a radiologist with expertise in prostate mpMRI to determine reason for discordance.
RESULTS: A total of 521 lesions were identified on mpMRI. 121/521 (23.2%), 310/524 (59.5%), and 90/521 (17.3%) were PI-RADS 5, 4, and 3, respectively. PPV of PI-RADS 5, 4, and 3 for all PCa and csPCa was 0.80, 0.55, 0.24 and 0.63, 0.33, and 0.09, respectively. 45 cases of discordant biopsy results for PI-RADS 5 lesions were found with 27 deemed "true" discordances or "unresolved" discordances where imaging re-review confirmed PI-RADS appropriateness, while 18 were deemed "false" or resolved discordances due to downgrading of PI-RADS scores based on imaging re-review. Adjusting for resolved discordances on re-review, the PPV of PI-RADS 5 lesions for csPCa was deemed to be 0.74 and upon adjusting for presence of csPCa found in cases of unresolved discordance, PPV rose to 0.83 for PI-RADS 5 lesions.
CONCLUSION: Although PIRADS 5 lesions are considered high risk for csPCa, the PPV is not 100% and a diagnostic dilemma occurs when targeted biopsy returns discordant. While PI-RADS score is downgraded in some cases upon imaging re-review, a number of "false" or "unresolved" discordances were identified in which MRI re-review confirmed initial PI-RADS score and subsequent pathology confirmed presence of csPCa in these lesions.
CLINICAL IMPACT: We propose a structured approach to resolving discordant biopsy results using multi-disciplinary re-review of imaging and archived biopsy strikes as a quality improvement pathway. Further work is needed to determine the value of re-biopsy in cases of unresolved discordance and to develop robust QI systems for prostate MRI.
引用
- Arcot, Sekar, Kotamarti, et al. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement. Abdom Radiol (NY). 2022. PMID: 35674785. doi:10.1007/s00261-022-03562-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。